Proliferative status is a risk index for recurrence in primary superficial (pTa/T1) low-grade urothelial bladder carcinoma

Acta Urologica Japonica

Volumn 49, Issue 11, 2003, Pages 649-658

  Su, Jing Shi ^a   Arima, Kiminobu ^a   Hasegawa, Mariko ^a   Franco, Omar E ^a   Yanagawa, Makoto ^a   Sugimura, Yoshiki ^a   Kawamura, Juichi ^b  

^a MIE UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b Ijinkai Takeda General Hospital   (Japan)

Author keywords

c erbB 2; Ki 67; p53; Recurrence; Superficial bladder cancer

Indexed keywords

ANTINEOPLASTIC AGENT; CYTARABINE; DOXORUBICIN; KI 67 ANTIGEN; MITOMYCIN C; MULTIDRUG RESISTANCE PROTEIN; PROTEIN P53;

ADULT; AGED; ARTICLE; BLADDER CANCER; BLADDER CARCINOMA; CANCER COMBINATION CHEMOTHERAPY; CANCER RECURRENCE; CELL PROLIFERATION; CYSTOSCOPY; FEMALE; GENE OVEREXPRESSION; HUMAN; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; ONCOGENE C ERB; PROGNOSIS; RISK; TRANSURETHRAL RESECTION; TREATMENT OUTCOME;

ADULT; AGED; AGED, 80 AND OVER; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; KI-67 ANTIGEN; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; PROTO-ONCOGENE PROTEINS C-BCL-2; RISK FACTORS; TUMOR SUPPRESSOR PROTEIN P53; URINARY BLADDER NEOPLASMS;

EID: 0348048646     PISSN: 00181994     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (30)

1. Herr HW: Natural history of superficial bladder tumors. 10-to 20-year follow-up of treated patients. World J Urol 15: 84-88, 1997
2. Yokokawa M, Fukui I, Sekine H, et al.: Intravesical recurrence and malignant progression in superficial bladder tumor. Jpn J Urol 76: 378-382, 1985
3. Millan-Rodriguez F, Chechile-Toniolo G, Salvador-Bayarri J, et al.: Multivariate analysis of the prognostic factors of primary superficial bladder cancer. J Urol 163: 73-78, 2000
4. Pfister C, Moore L, Allard P, et al. Predictive value of cell cycle markers p53, MDM2, p21, and Ki-67 in superficial bladder tumor recurrence. Clin Cancer Res 5: 4079-4084, 1999
5. Japanese Urological Association and the Japanese Society of Pathology. General rules for clinical and pathological studies on bladder, 3nd ed, Kanahara-Shuppan, Tokyo, 2001
6. Popov Z, Hoznek A, Colombel M, et al.: The prognostic value of p53 nuclear overexpression and MIB-1 as a proliferative marker in transitional cell carcinoma of the bladder. Cancer 80: 1472-1481, 1997
7. Oosterhuis JM, Schapers RF, Janssen-Heijnen ML, et al.: MIB-1 as a proliferative marker in transitional cell carcinoma of the bladder: clinical significance and comparison with other prognostic factors. Cancer 88: 2598-2605, 2000
8. Sgambato A, Migaldi M, Faraglia B, et al.: Cyclin D1 expression in papillary superficial bladder cancer: its association with other cell cycle-associated proteins, cell proliferation and clinical outcome. Int J Cancer 97: 671-678, 2002
9. Brausi M, Collette L, Kurth K, et al.: Variability in the recurrence rate at first follow-up cystoscopy after TUR in stage Ta T1 transitional cell carcinoma of the bladder: a combined analysis of seven EORTC studies. Eur Urol 41: 523-531, 2002
10. Vollmer RT, Humphrey PA, Swanson PE, et al.: Invasion of the bladder by transitional cell carcinoma, its relation to histological grade and expressiom of p53, MIB-1, c-erbB-2, epidermal growth factor receptor, and bcl-2. Cancer 82: 715-723, 1998
11. Thykjaer T, Workman C, Kruhoffer M, et al.: Identification of gene expressions in superficial and invasive human bladder. Cancer Res 61: 2492-2499, 2001
12. Simon R, Eltze E, Schafer KL, et al.: Cytogenetic analysis of multifocal bladder cancer supports a monoclonal origin and intraepithelial spread of tumor cells. Cancer Res 61: 355-362, 2001
13. van Tilborg AA, de Vries A, de Bont M, et al.: Molecular evolution of multiple recurrent cancers of the bladder. Hum Mol Genet 9: 2973-2980, 2000
14. Asakura T, Takano Y, Iki M, et al.: Predictive value of Ki-67 for recurrence and progression of superficial bladder cancer. J Urol 158: 385-388, 1997
15. Wu TT, Chen JH, Lee YH, et al.: The role of bcl-2, p53 and Ki-67 index in predicting tumor recurrence for low-grade superficial transitional cell bladder carcinoma. J Urol 163: 758-760, 2000
16. Streeter EH and Harris AL: Angiogenesis in bladder cancer-prognostic marker and target for future therapy. Surg Oncol 11: 85-100, 2002
17. Hashimoto Y and Shutou K: Differentiation inducement of cancer cells. In: Clinical Oncology. Edited by Japan Clinical Oncology Study Institute. pp 25-42, Cancer and Chemotherapy Publishers INC, Tokyo, 1996
18. Ushijima C, Tsukamoto S, Yamazaki K, et al.: High vascularity in the peripheral region of non-small cell lung cancer tissue is associated with tumor progression. Lung Cancer 34: 233-241, 2001
19. Ogura Y, Sato K, Kato T, et al.: Immunohistochemical analysis of expression of angiogenic factors and tumor angiogenesis in superficial bladder cancer. Jpn J Urol 89: 529-537, 1998
20. Popescu NC, King CR and Kraus MH: Localization of the human erbB-2 gene on normal and rearranged chromosomes 17 to bands q12-21.32. Genomics 4: 362-366, 1989
21. Kokai Y, Myers JN, Wada T, et al.: Synergistic interaction of p185c-neu and the EGF receptor leads to transformation of rodent fibroblasts. Cell 58: 287-292, 1989
22. Verbeek BS, Adriaansen-Slot SS, Vroom TM, et al.: Overexpression of EGFR and c-erbB2 causes enhanced cell migration in human breast cancer cells and NIH3T3 fibroblasts. FEBS Lett 425: 145-150, 1998
23. Chow NH, Chan SH, Tzai TS, et al.: Expression profiles of ErbB family receptors and prognosis in primary transitional cell carcinoma of the urinary bladder. Clin Cancer Res 7: 1957-1962, 2001
24. Gandour-Edwards R, Lara PN Jr, Folkins AK, et al.: Does HER2/neu expression provide prognostic information in patients with advanced urothelial carcinoma? Cancer 95: 1009-1015, 2002
25. Tetu B, Fradet Y, Allard P, et al.: Prevalence and clinical significance of HER-2/neu, p53 and Rb expression in primary superficial bladder cancer. J Urol 155: 1784-1788, 1996
26. Dahse R, Utting M, Werner W, et al.: TP53 alterations as a potential diagnostic marker in superficial bladder carcinoma and patient's serum, plasma and urine samples. Int J Oncol 20: 107-115, 2002
27. Serth J, Kuczyk MA, Bokemeyer C, et al.: p53 Immunohistochemistry as an independent prognostic factor for superficial transitional cell carcinoma of the bladder. Br J Cancer 71: 201-205, 1995
28. Cheng J, Huang H, Pak J, et al.: Allelic loss of p53 gene is associated with genesis and maintenance, but not invasion, of mouse carcinoma in situ of the bladder. Cancer Res 63: 179-185, 2003
29. Rosati A, Decorti G, Klugmann FB, et al.: Cytofluorimetric analysis of a renal tubular cell line and its resistant counterpart. Anticancer Res 20: 3403-3410, 2000
30. Kakehi Y: Molecular mechanisms of chemotherapeutic resistance in genitourinary cancers, Jpn J Urol 89: 1-13, 1998